{"name":"Tanabe Pharma Corporation","slug":"tanabe-pharma-corporation","ticker":"","exchange":"","domain":"tanabepharmacorporation.com","description":"","hq":"Chūō-ku","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":14,"colorKey":"cardiovascular","drugs":[{"name":"GLP-1 analogue","genericName":"GLP-1 analogue","slug":"glp-1-analogue","indication":"Other","status":"marketed"},{"name":"MCI-186","genericName":"MCI-186","slug":"mci-186","indication":"Acute ischemic stroke","status":"phase_3"},{"name":"MCI-186 in open label phase","genericName":"MCI-186 in open label phase","slug":"mci-186-in-open-label-phase","indication":"Ischemic stroke","status":"phase_3"},{"name":"MCI-196","genericName":"MCI-196","slug":"mci-196","indication":"Hyperphosphatemia in patients with chronic kidney disease on dialysis","status":"phase_3"},{"name":"MCI-9042","genericName":"MCI-9042","slug":"mci-9042","indication":"Transthyretin amyloidosis (ATTR amyloidosis)","status":"phase_3"},{"name":"MP-513","genericName":"MP-513","slug":"mp-513","indication":"IgA nephropathy","status":"phase_3"},{"name":"MT-3995 Low","genericName":"MT-3995 Low","slug":"mt-3995-low","indication":"Other","status":"phase_2"},{"name":"MT-5625 low dose","genericName":"MT-5625 low dose","slug":"mt-5625-low-dose","indication":"Other","status":"phase_1"},{"name":"MT-6548","genericName":"MT-6548","slug":"mt-6548","indication":"Muscle wasting / sarcopenia","status":"phase_3"},{"name":"MT-8554 high dose","genericName":"MT-8554 high dose","slug":"mt-8554-high-dose","indication":"Other","status":"phase_2"},{"name":"Placebo of MCI-186","genericName":"Placebo of MCI-186","slug":"placebo-of-mci-186","indication":"Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS)","status":"phase_3"},{"name":"Placebo of MCI-196","genericName":"Placebo of MCI-196","slug":"placebo-of-mci-196","indication":"Other","status":"phase_3"},{"name":"Placebo of MP-513","genericName":"Placebo of MP-513","slug":"placebo-of-mp-513","indication":"Other","status":"phase_3"},{"name":"glinide","genericName":"glinide","slug":"glinide","indication":"Other","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":9,"colorKey":"respiratory","drugs":[{"name":"Teneli / Teneli + SU","genericName":"Teneli / Teneli + SU","slug":"teneli-teneli-su","indication":"Type 2 diabetes mellitus (in combination with sulfonylurea)","status":"phase_3"},{"name":"Canagliflozin (TA-7284)","genericName":"Canagliflozin (TA-7284)","slug":"canagliflozin-ta-7284","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Colestimide","genericName":"colestilan","slug":"colestilan","indication":"Hyperlipidemia","status":"discontinued"},{"name":"TA-650","genericName":"TA-650","slug":"ta-650","indication":"Treatment of type 2 diabetes","status":"phase_3"},{"name":"TA-7284 Low","genericName":"TA-7284 Low","slug":"ta-7284-low","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"Teneli (Teneligliptin)","genericName":"Teneli (Teneligliptin)","slug":"teneli-teneligliptin","indication":"Type 2 diabetes mellitus","status":"marketed"},{"name":"Teneli / Teneli + pio","genericName":"Teneli / Teneli + pio","slug":"teneli-teneli-pio","indication":"Type 2 diabetes mellitus (monotherapy and combination therapy)","status":"phase_3"},{"name":"Teneligliptin + Sulfonylurea","genericName":"Teneligliptin + Sulfonylurea","slug":"teneligliptin-sulfonylurea","indication":"Type 2 diabetes mellitus","status":"phase_3"},{"name":"alpha-glucosidase inhibitor","genericName":"alpha-glucosidase inhibitor","slug":"alpha-glucosidase-inhibitor","indication":"Type 2 diabetes mellitus","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"immunology","drugs":[{"name":"DPT-IPV-Hib-High（Combined Vaccine）","genericName":"DPT-IPV-Hib-High（Combined Vaccine）","slug":"dpt-ipv-hib-high-combined-vaccine","indication":"Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children","status":"phase_3"},{"name":"DPT-IPV-Hib-Low（Combined Vaccine）","genericName":"DPT-IPV-Hib-Low（Combined Vaccine）","slug":"dpt-ipv-hib-low-combined-vaccine","indication":"Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children","status":"phase_3"},{"name":"MP-424","genericName":"MP-424","slug":"mp-424","indication":"Chronic hepatitis C virus infection","status":"phase_3"},{"name":"RBV(48 weeks)","genericName":"RBV(48 weeks)","slug":"rbv-48-weeks","indication":"Chronic hepatitis C","status":"phase_3"},{"name":"RBV(24 weeks)","genericName":"RBV(24 weeks)","slug":"rbv-24-weeks","indication":"Treatment of HIV-1 infection in combination with other antiretroviral agents","status":"phase_3"}]},{"name":"Hematology","slug":"hematology","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"infectious","drugs":[{"name":"Iron supplement A","genericName":"Iron supplement A","slug":"iron-supplement-a","indication":"Iron deficiency anemia","status":"marketed"},{"name":"Iron supplement D","genericName":"Iron supplement D","slug":"iron-supplement-d","indication":"Iron deficiency anemia","status":"phase_3"},{"name":"Iron supplement B","genericName":"Iron supplement B","slug":"iron-supplement-b","indication":"Iron deficiency anemia","status":"phase_3"},{"name":"Iron supplement C","genericName":"Iron supplement C","slug":"iron-supplement-c","indication":"Iron deficiency anemia","status":"marketed"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"rare","drugs":[{"name":"Placebo of Simvastatin","genericName":"Placebo of Simvastatin","slug":"placebo-of-simvastatin","indication":"Control arm in Phase 3 clinical trials of simvastatin (active comparator for hyperlipidemia/cardiovascular risk reduction)","status":"phase_3"},{"name":"Sodium Ozagrel","genericName":"Sodium Ozagrel","slug":"sodium-ozagrel","indication":"Acute ischemic stroke","status":"marketed"},{"name":"TA-7284 High","genericName":"TA-7284 High","slug":"ta-7284-high","indication":"Hypertension","status":"phase_3"},{"name":"Teneligliptin/Canagliflozin","genericName":"Teneligliptin/Canagliflozin","slug":"teneligliptin-canagliflozin","indication":"Type 2 diabetes mellitus","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"DPT-IPV","genericName":"DPT-IPV","slug":"dpt-ipv","indication":"Primary immunization against diphtheria, pertussis, tetanus, and poliomyelitis in infants and children","status":"phase_3"},{"name":"DPT-IPV-Hib","genericName":"DPT-IPV-Hib","slug":"dpt-ipv-hib","indication":"Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children","status":"phase_3"},{"name":"DPT-IPV-Hib (Combined Vaccine)","genericName":"DPT-IPV-Hib (Combined Vaccine)","slug":"dpt-ipv-hib-combined-vaccine","indication":"Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"neuroscience","drugs":[{"name":"IFN beta(48 weeks)","genericName":"IFN beta(48 weeks)","slug":"ifn-beta-48-weeks","indication":"Multiple sclerosis (relapsing-remitting or secondary progressive forms)","status":"phase_3"},{"name":"IFN beta(24 weeks)","genericName":"IFN beta(24 weeks)","slug":"ifn-beta-24-weeks","indication":"Multiple sclerosis (relapsing-remitting or secondary progressive forms)","status":"phase_3"},{"name":"TAU-284","genericName":"TAU-284","slug":"tau-284","indication":"Alzheimer's disease","status":"phase_3"}]}],"pipeline":[{"name":"DPT-IPV","genericName":"DPT-IPV","slug":"dpt-ipv","phase":"phase_3","mechanism":"DPT-IPV is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, and inactivated poliovirus.","indications":["Primary immunization against diphtheria, pertussis, tetanus, and poliomyelitis in infants and children","Booster immunization in pediatric populations"],"catalyst":""},{"name":"DPT-IPV-Hib-High（Combined Vaccine）","genericName":"DPT-IPV-Hib-High（Combined Vaccine）","slug":"dpt-ipv-hib-high-combined-vaccine","phase":"phase_3","mechanism":"This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b.","indications":["Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children"],"catalyst":""},{"name":"DPT-IPV-Hib-Low（Combined Vaccine）","genericName":"DPT-IPV-Hib-Low（Combined Vaccine）","slug":"dpt-ipv-hib-low-combined-vaccine","phase":"phase_3","mechanism":"This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b pathogens.","indications":["Prevention of diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b infection in infants and children"],"catalyst":""},{"name":"GLP-1 analogue","genericName":"GLP-1 analogue","slug":"glp-1-analogue","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"IFN beta(48 weeks)","genericName":"IFN beta(48 weeks)","slug":"ifn-beta-48-weeks","phase":"phase_3","mechanism":"Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.","indications":["Multiple sclerosis (relapsing-remitting or secondary progressive forms)"],"catalyst":""},{"name":"Iron supplement A","genericName":"Iron supplement A","slug":"iron-supplement-a","phase":"marketed","mechanism":"Iron supplement A provides bioavailable iron to replenish depleted iron stores and support hemoglobin synthesis.","indications":["Iron deficiency anemia"],"catalyst":""},{"name":"Iron supplement D","genericName":"Iron supplement D","slug":"iron-supplement-d","phase":"phase_3","mechanism":"Iron supplement D replenishes iron stores to treat or prevent iron deficiency anemia.","indications":["Iron deficiency anemia"],"catalyst":""},{"name":"MP-424","genericName":"MP-424","slug":"mp-424","phase":"phase_3","mechanism":"MP-424 is a hepatitis C virus (HCV) NS3/4A protease inhibitor that blocks viral replication by preventing the cleavage of viral polyproteins.","indications":["Chronic hepatitis C virus infection"],"catalyst":""},{"name":"RBV(48 weeks)","genericName":"RBV(48 weeks)","slug":"rbv-48-weeks","phase":"phase_3","mechanism":"Ribavirin is an antiviral medication that works by inhibiting viral RNA synthesis.","indications":["Chronic hepatitis C","Hepatitis C in combination with other medications"],"catalyst":""},{"name":"Teneli / Teneli + SU","genericName":"Teneli / Teneli + SU","slug":"teneli-teneli-su","phase":"phase_3","mechanism":"Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals.","indications":["Type 2 diabetes mellitus (in combination with sulfonylurea)"],"catalyst":""},{"name":"Canagliflozin (TA-7284)","genericName":"Canagliflozin (TA-7284)","slug":"canagliflozin-ta-7284","phase":"marketed","mechanism":"Canagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney, reducing glucose reabsorption and increasing urinary glucose excretion to lower blood glucose levels.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Colestimide","genericName":"colestilan","slug":"colestilan","phase":"discontinued","mechanism":"Colestimide works by inhibiting the absorption of cholesterol and/or phosphorus in the intestines.","indications":["Hyperlipidemia","Hyperphosphatemia"],"catalyst":""},{"name":"DPT-IPV-Hib","genericName":"DPT-IPV-Hib","slug":"dpt-ipv-hib","phase":"phase_3","mechanism":"DPT-IPV-Hib is a combination vaccine that provides immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b through inactivated pathogen antigens and toxoids.","indications":["Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children"],"catalyst":""},{"name":"DPT-IPV-Hib (Combined Vaccine)","genericName":"DPT-IPV-Hib (Combined Vaccine)","slug":"dpt-ipv-hib-combined-vaccine","phase":"phase_3","mechanism":"This combined vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b.","indications":["Primary immunization against diphtheria, pertussis, tetanus, poliomyelitis, and Haemophilus influenzae type b in infants and children"],"catalyst":""},{"name":"IFN beta(24 weeks)","genericName":"IFN beta(24 weeks)","slug":"ifn-beta-24-weeks","phase":"phase_3","mechanism":"Interferon beta activates innate immune responses by binding to interferon-beta receptors on immune cells, enhancing antiviral and immunomodulatory activity.","indications":["Multiple sclerosis (relapsing-remitting or secondary progressive forms)"],"catalyst":""},{"name":"Iron supplement B","genericName":"Iron supplement B","slug":"iron-supplement-b","phase":"phase_3","mechanism":"Iron supplement B replenishes iron stores to treat or prevent iron deficiency anemia by restoring hemoglobin production.","indications":["Iron deficiency anemia"],"catalyst":""},{"name":"Iron supplement C","genericName":"Iron supplement C","slug":"iron-supplement-c","phase":"marketed","mechanism":"Iron supplement C replenishes iron stores to treat or prevent iron deficiency anemia by providing bioavailable iron for hemoglobin synthesis.","indications":["Iron deficiency anemia","Iron supplementation in iron-deficient patients"],"catalyst":""},{"name":"MCI-186","genericName":"MCI-186","slug":"mci-186","phase":"phase_3","mechanism":"MCI-186 is a free radical scavenger that neutralizes reactive oxygen species and reduces oxidative stress in neuronal tissue.","indications":["Acute ischemic stroke","Amyotrophic lateral sclerosis (ALS)"],"catalyst":""},{"name":"MCI-186 in open label phase","genericName":"MCI-186 in open label phase","slug":"mci-186-in-open-label-phase","phase":"phase_3","mechanism":"MCI-186 is a free radical scavenger.","indications":["Ischemic stroke"],"catalyst":""},{"name":"MCI-196","genericName":"MCI-196","slug":"mci-196","phase":"phase_3","mechanism":"MCI-196 is a phosphate binder that reduces serum phosphate levels by binding phosphate in the gastrointestinal tract.","indications":["Hyperphosphatemia in patients with chronic kidney disease on dialysis","Hyperphosphatemia in patients with chronic kidney disease not on dialysis"],"catalyst":""},{"name":"MCI-9042","genericName":"MCI-9042","slug":"mci-9042","phase":"phase_3","mechanism":"MCI-9042 is a selective inhibitor of transthyretin (TTR) amyloid fibril formation that prevents the aggregation and deposition of misfolded transthyretin protein.","indications":["Transthyretin amyloidosis (ATTR amyloidosis)"],"catalyst":""},{"name":"MP-513","genericName":"MP-513","slug":"mp-513","phase":"phase_3","mechanism":"MP-513 is a selective antagonist of the complement C5a receptor that inhibits complement-mediated inflammation.","indications":["IgA nephropathy","C3 glomerulopathy"],"catalyst":""},{"name":"MT-3995 Low","genericName":"MT-3995 Low","slug":"mt-3995-low","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MT-5625 low dose","genericName":"MT-5625 low dose","slug":"mt-5625-low-dose","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"MT-6548","genericName":"MT-6548","slug":"mt-6548","phase":"phase_3","mechanism":"MT-6548 is a selective androgen receptor modulator (SARM) that activates androgen signaling in muscle and bone while minimizing effects on prostate and other androgen-sensitive tissues.","indications":["Muscle wasting / sarcopenia","Bone health / osteoporosis"],"catalyst":""},{"name":"MT-8554 high dose","genericName":"MT-8554 high dose","slug":"mt-8554-high-dose","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Placebo of MCI-186","genericName":"Placebo of MCI-186","slug":"placebo-of-mci-186","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":["Control arm in phase 3 trials for amyotrophic lateral sclerosis (ALS)"],"catalyst":""},{"name":"Placebo of MCI-196","genericName":"Placebo of MCI-196","slug":"placebo-of-mci-196","phase":"phase_3","mechanism":"This is a placebo control arm and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of MP-513","genericName":"Placebo of MP-513","slug":"placebo-of-mp-513","phase":"phase_3","mechanism":"This is a placebo control and contains no active pharmaceutical ingredient.","indications":[],"catalyst":""},{"name":"Placebo of Simvastatin","genericName":"Placebo of Simvastatin","slug":"placebo-of-simvastatin","phase":"phase_3","mechanism":"This is a placebo control formulation used in clinical trials to compare against the active simvastatin drug and has no therapeutic mechanism.","indications":["Control arm in Phase 3 clinical trials of simvastatin (active comparator for hyperlipidemia/cardiovascular risk reduction)"],"catalyst":""},{"name":"RBV(24 weeks)","genericName":"RBV(24 weeks)","slug":"rbv-24-weeks","phase":"phase_3","mechanism":"Ritonavir is a protease inhibitor used to treat HIV/AIDS by preventing the replication of the virus.","indications":["Treatment of HIV-1 infection in combination with other antiretroviral agents"],"catalyst":""},{"name":"Sodium Ozagrel","genericName":"Sodium Ozagrel","slug":"sodium-ozagrel","phase":"marketed","mechanism":"Sodium ozagrel inhibits thromboxane A2 synthetase, reducing platelet aggregation and thrombosis.","indications":["Acute ischemic stroke","Prevention of thrombotic events in cardiovascular disease"],"catalyst":""},{"name":"TA-650","genericName":"TA-650","slug":"ta-650","phase":"phase_3","mechanism":"TA-650 is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","indications":["Treatment of type 2 diabetes"],"catalyst":""},{"name":"TA-7284 High","genericName":"TA-7284 High","slug":"ta-7284-high","phase":"phase_3","mechanism":"TA-7284 High is a drug that targets the renin-angiotensin system.","indications":["Hypertension"],"catalyst":""},{"name":"TA-7284 Low","genericName":"TA-7284 Low","slug":"ta-7284-low","phase":"phase_3","mechanism":"TA-7284 is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that reduces blood glucose by increasing urinary glucose excretion.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"TAU-284","genericName":"TAU-284","slug":"tau-284","phase":"phase_3","mechanism":"Tau-284 is a tau aggregation inhibitor.","indications":["Alzheimer's disease"],"catalyst":""},{"name":"Teneli (Teneligliptin)","genericName":"Teneli (Teneligliptin)","slug":"teneli-teneligliptin","phase":"marketed","mechanism":"Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the action of incretin hormones to increase insulin secretion and reduce glucagon in response to meals.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Teneli / Teneli + pio","genericName":"Teneli / Teneli + pio","slug":"teneli-teneli-pio","phase":"phase_3","mechanism":"Teneli is a DPP-4 inhibitor that increases incretin levels to enhance insulin secretion and reduce glucagon in response to meals, improving glycemic control in type 2 diabetes.","indications":["Type 2 diabetes mellitus (monotherapy and combination therapy)"],"catalyst":""},{"name":"Teneligliptin + Sulfonylurea","genericName":"Teneligliptin + Sulfonylurea","slug":"teneligliptin-sulfonylurea","phase":"phase_3","mechanism":"Teneligliptin inhibits dipeptidyl peptidase-4 (DPP-4) to increase incretin levels and lower blood glucose, while the sulfonylurea component stimulates pancreatic beta cells to release insulin.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"Teneligliptin/Canagliflozin","genericName":"Teneligliptin/Canagliflozin","slug":"teneligliptin-canagliflozin","phase":"phase_3","mechanism":"Teneligliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor, while Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor.","indications":["Type 2 diabetes mellitus","Hypertension"],"catalyst":""},{"name":"alpha-glucosidase inhibitor","genericName":"alpha-glucosidase inhibitor","slug":"alpha-glucosidase-inhibitor","phase":"marketed","mechanism":"Alpha-glucosidase inhibitors slow the digestion and absorption of carbohydrates in the small intestine, reducing postprandial blood glucose spikes.","indications":["Type 2 diabetes mellitus"],"catalyst":""},{"name":"glinide","genericName":"glinide","slug":"glinide","phase":"phase_3","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxORTNtQnpiVGUtcXlSREZ4bW9QNkg5WVQtdlZydVVCLU5zYmVTSjlUWkNBMlVsUG9iWlpxdUdwVDloZTd4U3otQ1VkWW1SLVl5YldWZTVULUhuaGdlMHlzRmZJM0dLUDc4ZXNKQXFuZjE0VGV3RmpXeEVUQXM5N2EyY2piWllvNFc4X3V3LXVzYnM2S0ozc1FqLUxGS3NHZnNJbnBwWDdIbHEwU01Xb24yT05OUjRnQi1XRmZTT2tjVTREWHQ4QlM3NllHc3NENEZ2Nmk4X0NvdU5zYlVrMlJ3akR4LUxFWWVZSWxpS1RaYUpjTG52cUxaaHFzOHVFbktNRTU0aE0wS3FRcVNSQTlhamR1bDBjcHF2TnVGTlNwQ1NYZDNCSVhYcw?oc=5","date":"2026-04-01","type":"pipeline","source":"Block Island Times","summary":"Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi - Block Island Times","headline":"Tanabe Pharma America Announces Finalization of RADICAVA (edaravone) Transfer to Shionogi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQOXZIT3dSbkRxY3lrT1JybVd4TFNLSlBqUGR5akJKU3daVzk4N1pjR3dCT003UURnYl9VeWhmY19VZHRfVHJNTGhWTWl6UTR5cGpvdE9sdmZmUGJwRFNILXNmSUM1Q21JQjRHdWJqUXFLVnNOUWtMQmlQenhpd09ZSUtSUW40Z2FsYkJpZTRELVR4bzFVR2ZmM0laMDRUdW02emJVYkUxWUxMbFJPSVdXSmY1enZmbndjS0VjYw?oc=5","date":"2026-01-20","type":"regulatory","source":"Fierce Biotech","summary":"Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark - Fierce Biotech","headline":"Tanabe Pharma's oral drug scores in ph. 3 rare disease study, though details remain in the dark","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxQcWR1THQ5di1TMWpFRHhPUkN5V2pjZzZsNkYtMndxeHphdzNid3lCc0d5QVVkR25Ra1g1MFdlbV9xSTNiQVZfb1JlbGN6U2hJWTdMdmNTc3BRcWk2UVBiWHZYdi04ck1ITFV4eFpxUUU1dnRrZndtQlEtTHVQQ1RWcE03VU5IMEM5YkxLMFNCZzVMbk9oeTl2RW9KcHBZZ2pXZVRKZ1c0cWl5RFJHaXFjQnZ0TQ?oc=5","date":"2026-01-20","type":"trial","source":"Clinical Trials Arena","summary":"Tanabe Pharma’s dersimelagon hits success in Phase III EPP and XLP trial - Clinical Trials Arena","headline":"Tanabe Pharma’s dersimelagon hits success in Phase III EPP and XLP trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxOMXBBb2ZIb1NoSUE5aUl1UktWVUVDUWpjS3VqM0wzRWpJYnhPRG8wRm9WU24wd1FObUticHBTUGlOd1pGZWVvemtZc0k4YnNEdE93eHJDODFKdGpYV2QxM0xPVU9DSVpVekZNMk8yV1lPN3A3RmZQUklpWXltSUdsZHZCcUxGbVA0UkpPX1VzcHVqbEFacWx5eTBna0VJVEI4OWZlVS1nVU9PTWh2a3I2bDlGWXpqOVVvS1FQbGs3NWdORFJfaDF3T3lIVG1heXc?oc=5","date":"2025-12-23","type":"pipeline","source":"Cleary Gottlieb","summary":"Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA - Cleary Gottlieb","headline":"Shionogi in Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® and IV RADICAVA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE9BV3h2N2ZjNlpXRFlpNnZNTTR0Wm1VU091ejgtcE1zWmJKX3paTm42SWg0cXRpWFZocEpjUUs2ZXBHdGtMbzNNRkZtem9DYTg5NG5Cc1U3Q09ieldQek15N25HMlBlUnVtVmlCTVQ2YlZZYWN0d0pz?oc=5","date":"2025-12-23","type":"deal","source":"NJBIZ","summary":"Shionogi to buy Jersey City pharma for $2.5B - NJBIZ","headline":"Shionogi to buy Jersey City pharma for $2.5B","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwJBVV95cUxNZDI5RGVHNC1hYk9aR05xWFlpZUNrakVrUmNrT010aEgzZnk5YjI2eWd0Q3pBQTZla3gwU24wQTZDdDRXT2xUd3FSNkRaSDRqZzNxWlN3R1ZjdTlRbWhFSTctTzRTQzVIcEgxN0RMcTN5ZWJtMUt3QnFIbXR4UnJOakM2QUY2NUxRdTEwQ2xJa3k3SktxUFo4Z1FXVUR3ckszTHB2TmhqNkV0clphajJMR0JIaVJWQXVITlpYQWVpLU1KVC1DT0N0Y2oyUzhvVVU0dmg1c1kydjFJdE0wN0M4cGhrRi1KLUozZHhsdHpJUXhnOHhTRGFzNGlwbnJJWWNvMTJ6SEUyTDBfWUdoNGttbWtydFlKWTVWUE9mTnNpd0lSSkloTURQVHVfNkdJbFk?oc=5","date":"2025-12-22","type":"pipeline","source":"businesswire.com","summary":"Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA ORS® (edaravone) and IV RADICAVA - businesswire.com","headline":"Shionogi Expands Rare Disease Presence with Planned Acquisition of Global Rights to Tanabe Pharma Corporation’s RADICAVA","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNZ2NyOW1zOTQ4dXRiWEtmeTlCUmVsSHN5Mi1uRFZiSlp4UjBzLTI5MFlSQjMzNlNIVF9OVkRsNFpSTlJrdnp4a0ktZUpwRWhnZHMtb3BQbGxZYnVhakZzeklrLWRjSExRbExsOUJiV0F6bWJRa1BLRXlxdGJ4R3YyZXpOX0wtajNjdG1mblpLUGRBTV93ZVNJUENhVjZ2c2RLc3I3Q081MDZ1RS03T3NJZjNUbVctQQ?oc=5","date":"2025-12-09","type":"pipeline","source":"Bloomberg.com","summary":"Bain Is Said to Mull Selling Tanabe Pharma’s Non-Japanese Assets - Bloomberg.com","headline":"Bain Is Said to Mull Selling Tanabe Pharma’s Non-Japanese Assets","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNUVVJY1piSDhnS282S1h5eEV3QVdueWFDbkU1MEMtRHFSay1jZDdNNkNoZFJZUTNiZWk5eWwzaWlDaDJrczNTVzlqV3NZSnZJZ0QyaXJ0aHpxSWpUVEFXLWRteWRKV2cyODV3ckc1N0lwSXFLeklvcDVSNG9KY2lVM01EcHkxT2xvNmcwRkE5R0dYUzBkc0pucWlBSjJOcnBGZmlWcWgxTXVMSUJxT3QwWWg0N2dWazVT?oc=5","date":"2025-12-01","type":"pipeline","source":"prnewswire.com","summary":"Mitsubishi Tanabe Pharma America is Now Tanabe Pharma America - prnewswire.com","headline":"Mitsubishi Tanabe Pharma America is Now Tanabe Pharma America","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQVGFUOVhJTEYwblcwa2tnTHJIcVdWbGxCTzlvSG93b0VIVnVGd1NtZnhIdUw0ZTZTWGxFc19ZSmg5ODB1QzZoQkxFVmd0VkUyUHlpZ25XZzlHNmRDeFBuWjJoeVBYaDhLWmNTYjVSbjZhRWdhUFp4MWdZaWFGaHJiR0NDWUtrQS1INXQxSTQwU0gwSm5HZjVNVkVzRGRFMUlJZFc0b0FmbDJ6cVZZeHpRM1FONmtkbDlocGhwb0V1TUkyS3ZuWEE?oc=5","date":"2025-12-01","type":"deal","source":"Fierce Pharma","summary":"Tanabe Pharma shifts gears for Bain-backed future, dropping Mitsubishi moniker after $3.3B deal - Fierce Pharma","headline":"Tanabe Pharma shifts gears for Bain-backed future, dropping Mitsubishi moniker after $3.3B deal","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOMVZzNkN1bHJIWVZ5RWw5bjloR0dzSHpabUxlekRMN3QwZjEzSEltanY5ZWJUS0RkUDlSN2o4Q1JYNkEzTDZ5aGpXLXBPa3BJd0pIWGw4enlLUHZOemROVGxkeDJzdFpvWnpHSVEwbTRqSFU1UThJOUQ5TDNXWjdMZXYwTV9zTS1NZ2VpSU83LVBWT1lfaHVUSUUyUl8yX1kyd1VKdjFIalhuWndob3FxdGd3?oc=5","date":"2025-12-01","type":"pipeline","source":"newswire.ca","summary":"Mitsubishi Tanabe Pharma Canada is Now Tanabe Pharma Canada - newswire.ca","headline":"Mitsubishi Tanabe Pharma Canada is Now Tanabe Pharma Canada","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwJBVV95cUxPcjFscERKc1ZZN0tnTjQwRVNWcm9icGZud1FQNzR3TUpQMWNnRFRRTjN4QkRVQjNBVGlKYWNvUjE2Tnd0dnhLeks3ZlBIbVRPRVhFRHJJbTRqRndNRUt0Q1RXYVlaUWFoLUw2bll6QUhFeHBJcUhxVUEtcTBhZVFXT2VrcThKazRvQ2ZJVy0wLXhHczhvaGVSRVlKM1kzcXJPRENlNVA5eDA2ZVVSMmkyclRpUXh5aWt3aUZ1a3hYdUtkYTlxbWdtRkd0ZUQ4TjkzOWhDYy1nSnJ5TFhMNnFBWm12blpZY2U5M3BFbnZ3U3AxczlHV1JzZlRmbDZVLWF4V2o4Ny1NWWxfcHIyNmtORXFveURtRXQ3UVVkSDBZSQ?oc=5","date":"2025-11-25","type":"deal","source":"prnewswire.com","summary":"GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe Pharma Corporation - prnewswire.com","headline":"GV20 Therapeutics Announces Achievement of Milestone under Antibody-Drug Conjugate Collaboration with Mitsubishi Tanabe ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPc2g0MFFBZk9IVjg5OG1mdy1xODN3dlBVdjRPZGctN2x0b1Zta3Q3Xy1HVFBURmN0TkpkVnFFSFdVbXhhR3F5WGVWUi1XeE45RFAweUsxaTdlN1hJbVdSYjJEb3RKOWw4QTF3SlFtaVF0WVRuSHlscW1WRGVEZXJhaW8tVnhWUQ?oc=5","date":"2025-06-13","type":"pipeline","source":"JAPAN Forward","summary":"Japan's Oldest Pharma Firm to Be Sold to Bain Capital - JAPAN Forward","headline":"Japan's Oldest Pharma Firm to Be Sold to Bain Capital","sentiment":"neutral"}],"patents":[],"drugCount":42,"phaseCounts":{"phase_3":31,"marketed":7,"discontinued":1,"phase_2":2,"phase_1":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}